Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Three members of FDA advisory committee resign after aducanumab approval

By Brian Buntz | June 10, 2021

FDA logoFDA’s decision to conditionally approve Biogen’s Aduhelm (aducanumab) continues to cause controversy.

Three members of FDA’s Peripheral and Central Nervous System Drugs Advisory Committee have resigned. The most recent include David S. Knopman, a neurologist at the Mayo Clinic (Rochester, Minn.) and Aaron Kesselheim, a professor at Harvard University (Cambridge, Mass.)

Last November, eight committee members disagreed that there was sufficient clinical trial evidence to suggest that the drug was effective against Alzheimer’s. Another was undecided.

The first to resign was Joel Perlmutter, a neurologist at Washington University (St. Louis).

The three have not gone quietly.

In a letter to acting FDA Commissioner Janet Woodcock, Kesselheim called the aducanumab approval the “worst drug approval decision in recent U.S. history.”

Knopman told The Washington Post that he did not “wish to be part of a sham process.”

Perlmutter was more reserved, simply expressing his frustration at the FDA’s decision to approve aducanumab “without further discussion with our advisory committee.”

Before the FDA advisory committee convened last November, the FDA had signaled its support for the drug, indicating that there was “substantial evidence of effectiveness to support approval.”

The Peripheral and Central Nervous System Drugs Advisory Committee traditionally has ten members. Knopman had been a site investigator in the aducanumab trials and was thus recused from the November advisory committee meeting.

Aducanumab is the first FDA-approved Alzheimer’s therapy since 2003.

In one sense, the approval is unlikely as Biogen and its partner Eisai announced in March 2019 that they would discontinue two Phase 3 clinical trials for aducanumab based on an unfavorable futility analysis. By October 2019, Biogen had reversed course, arguing that the drug appeared to be effective after all.


Filed Under: Neurological Disease
Tagged With: Aducanumab, Aduhelm, Alzheimer's disease, Alzheimer’s, Biogen, Eisai, FDA, Peripheral and Central Nervous System Drugs Advisory Committee
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Aduhelm
Nine out of ten U.S. neurologists have Aduhelm efficacy doubts
Athira Pharma
​​Athira Pharma to continue open-label Alzheimer’s extension studies
Biogen
Biogen CEO Michel Vounatsos to step aside as Aduhelm sales continue to sputter
Janssen
Why Janssen’s nipocalimab could represent a ‘pipeline in a pathway’

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50